This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.
This study enrolled and implanted 133 subjects at 15 sites in the US under the original IDE. Subjects were given the option to extend out to 3 years post activation, with annual visits at 2 and 3 years post activation (96 and 144 weeks post-activation). Subjects who are still active in the original IDE study will be offered consecutive enrollment in the post approval study and will be given the option to receive a new implant. Subjects who are no longer active, or have exited the study will be given the option to reenter the study and complete two follow-up visits. Subjects re-entering the study will not have the option to receive a new implant. Post approval follow-up of subjects will occur through the year 5 visit (257 weeks post-activation of their original device). Reimplantation of a new eCoin would not reset their follow-up clock.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
133
Subcutaneous stimulation of the tibial nerve using the eCoin device.
Kaiser Permanente
Downey, California, United States
Sequoia Urology Center
Redwood City, California, United States
Kaiser Permanente
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 48 weeks after device activation.
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
All adverse events will be reported in all patients up to 52 weeks after implantation.
Time frame: 52 weeks after implantation.
Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
All adverse events will be reported.
Time frame: 28 weeks after implantation
Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Moderate-term effectiveness data, responder rate
Time frame: 24 weeks after device activation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary
Responder rate
Time frame: 96 weeks after device activation.
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 144 weeks after device activation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
San Diego, California, United States
Sansum Clinic
Santa Barbara, California, United States
SurgOne PC
Englewood, Colorado, United States
Urology Associates of Norwalk
Norwalk, Connecticut, United States
Florida Bladder Institute
Naples, Florida, United States
North Shore Medical Group
Skokie, Illinois, United States
UnityPoint Clinic
Waterloo, Iowa, United States
Chesapeake Urology
Owings Mills, Maryland, United States
...and 5 more locations
Responder rate
Time frame: 205 weeks after device activation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 257 weeks after device activation
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.
All adverse events will be reported in all patients up to 96 weeks after implantation.
Time frame: 96 weeks after implantation
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events
All adverse events will be reported in all patients up to 144 weeks after implantation.
Time frame: 144 weeks after implantation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
All adverse events will be reported in all patients up to 205 weeks after implantation.
Time frame: 205 weeks after implantation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
All adverse events will be reported in all patients up to 257 weeks after implantation.
Time frame: 257 weeks after implantation